Telomerase inhibition in malignant gliomas: a systematic review

Abstract Glioblastoma (GBM) is the most frequent adult malignant brain tumour and despite different therapeutic efforts, the median overall survival still ranges from 14 to 18 months. Thus, new therapeutic strategies are urgently needed. However, the identification of cancer-specific targets is particularly challenging in GBM, due to the high heterogeneity of this tumour in terms of histopathological, molecular, genetic and epigenetic features. Telomerase reactivation is a hallmark of malignant glioma. An activating mutation of the hTERT gene, encoding for the active subunit of telomerase, is one of the molecular criteria to establish a diagnosis of GBM, IDH-wildtype, in the 2021 WHO classification of central nervous system tumours. Telomerase inhibition therefore represents, at least theoretically, a promising strategy for GBM therapy: pharmacological compounds, as well as direct gene expression modulation therapies, have been successfully employed in in vitro and in vivo settings. Unfortunately, the clinical applications of telomerase inhibition in GBM are currently scarce. The aim of the present systematic review is to provide an up-to-date report on the studies investigating telomerase inhibition as a therapeutic strategy for malignant glioma in order to foster the future translational and clinical research on this topic.

[1]  J. Feigon,et al.  Telomerase structural biology comes of age. , 2022, Current opinion in structural biology.

[2]  S. Verstovsek,et al.  Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design. , 2022, Future oncology.

[3]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[4]  H. Kim,et al.  Inhibition of MUC1 exerts cell-cycle arrest and telomerase suppression in glioblastoma cells , 2020, Scientific Reports.

[5]  M. Blasco,et al.  miR-490 suppresses telomere maintenance program and associated hallmarks in glioblastoma , 2020, Cellular and molecular life sciences : CMLS.

[6]  A. Olivi,et al.  Tailored therapy for recurrent glioblastoma. Report of a personalized molecular approach. , 2020, Journal of neurosurgical sciences.

[7]  Zhan-guo Wang,et al.  Antitumor activity and mechanism of costunolide and dehydrocostus lactone: Two natural sesquiterpene lactones from the Asteraceae family. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[8]  K. Tamura,et al.  Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts , 2019, Cancer science.

[9]  A. Sgura,et al.  Epigallocatechin‐3‐gallate induces telomere shortening and clastogenic damage in glioblastoma cells , 2019, Environmental and molecular mutagenesis.

[10]  Jun S. Song,et al.  Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. , 2018, Cancer cell.

[11]  Ç. Biray Avcı,et al.  Effects of telomerase inhibitor on epigenetic chromatin modification enzymes in malignancies , 2018, Journal of cellular biochemistry.

[12]  M. Venkataswamy,et al.  Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells , 2018, Cytotechnology.

[13]  Harshil Dhruv,et al.  When the Ends Are Really the Beginnings: Targeting Telomerase for Treatment of GBM , 2018, Current Neurology and Neuroscience Reports.

[14]  M. Blasco,et al.  Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts. , 2017, Cancer cell.

[15]  Azin Mirzazadeh,et al.  Assessment Effects of Resveratrol on Human Telomerase Reverse Transcriptase Messenger Ribonucleic Acid Transcript in Human Glioblastoma , 2017, Advanced biomedical research.

[16]  M. Venkataswamy,et al.  RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells , 2016, Cytotechnology.

[17]  E. Miyaoka,et al.  A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas , 2016, Acta neuropathologica communications.

[18]  C. Sarkar,et al.  Nrf2-driven TERT regulates pentose phosphate pathway in glioblastoma , 2016, Cell Death and Disease.

[19]  Gang Zhao,et al.  Telomere targeting with a novel G-quadruplex-interactive ligand BRACO-19 induces T-loop disassembly and telomerase displacement in human glioblastoma cells , 2016, Oncotarget.

[20]  M. Hande,et al.  Plumbagin alters telomere dynamics, induces DNA damage and cell death in human brain tumour cells. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.

[21]  J. Honnorat,et al.  Telomerase inhibition improves tumor response to radiotherapy in a murine orthotopic model of human glioblastoma , 2015, Molecular Cancer.

[22]  M. Hande,et al.  Targeting DNA-PKcs and telomerase in brain tumour cells , 2014, Molecular Cancer.

[23]  R. Grundy,et al.  RHPS4 G-Quadruplex Ligand Induces Anti-Proliferative Effects in Brain Tumor Cells , 2014, PloS one.

[24]  M. Hande,et al.  Curcumin inhibits telomerase and induces telomere shortening and apoptosis in brain tumour cells , 2013, Journal of cellular biochemistry.

[25]  M. Hande,et al.  Genistein induces growth arrest and suppresses telomerase activity in brain tumor cells , 2012, Genes, chromosomes & cancer.

[26]  Guan Sun,et al.  MiR‐21 Modulates hTERT Through a STAT3‐Dependent Manner on Glioblastoma Cell Growth , 2012, CNS neuroscience & therapeutics.

[27]  R. Stupp,et al.  Current concepts and management of glioblastoma , 2011, Annals of neurology.

[28]  H. Harn,et al.  Butylidenephthalide Suppresses Human Telomerase Reverse Transcriptase (TERT) in Human Glioblastomas , 2011, Annals of Surgical Oncology.

[29]  M. Hande,et al.  Thymoquinone Induces Telomere Shortening, DNA Damage and Apoptosis in Human Glioblastoma Cells , 2010, PloS one.

[30]  E. Maher,et al.  The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth , 2010, Clinical Cancer Research.

[31]  N. Banik,et al.  Combination of hTERT Knockdown and IFN-γ Treatment Inhibited Angiogenesis and Tumor Progression in Glioblastoma , 2009, Clinical Cancer Research.

[32]  L. Ricci-Vitiani,et al.  Inhibition of telomerase in the endothelial cells disrupts tumor angiogenesis in glioblastoma xenografts , 2008, International journal of cancer.

[33]  M. Hande,et al.  Inhibition of telomerase activity and human telomerase reverse transcriptase gene expression by histone deacetylase inhibitor in human brain cancer cells. , 2007, Mutation research.

[34]  N. Banik,et al.  Differentiation Decreased Telomerase Activity in Rat Glioblastoma C6 Cells and Increased Sensitivity to IFN-γ and Taxol for Apoptosis , 2007, Neurochemical Research.

[35]  R. Pallini,et al.  Telomerase inhibition impairs tumor growth in glioblastoma xenografts , 2006, Neurological research.

[36]  M. Blasco,et al.  Telomerase regulation and stem cell behaviour. , 2006, Current opinion in cell biology.

[37]  R. Pallini,et al.  Telomerase inhibition by stable RNA interference impairs tumor growth and angiogenesis in glioblastoma xenografts , 2006, International journal of cancer.

[38]  K. Lamborn,et al.  Antitumor effects of specific telomerase inhibitor GRN163 in human glioblastoma xenografts. , 2004, Neuro-oncology.

[39]  O. Chinot,et al.  Clinical implications of quantitative real-time RT–PCR analysis of hTERT gene expression in human gliomas , 2003, British Journal of Cancer.

[40]  H. Kiaris,et al.  Decrease in telomerase activity in U-87MG human glioblastomas after treatment with an antagonist of growth hormone-releasing hormone. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.